Skip to Content

Generic Briviact Availability

Briviact is a brand name of brivaracetam, approved by the FDA in the following formulation(s):

BRIVIACT (brivaracetam - solution;intravenous)

  • Manufacturer: UCB INC
    Approval date: May 12, 2016
    Strength(s): 50MG/5ML (10MG/ML) [RLD]

BRIVIACT (brivaracetam - solution;oral)

  • Manufacturer: UCB INC
    Approval date: May 12, 2016
    Strength(s): 10MG/ML [RLD]

BRIVIACT (brivaracetam - tablet;oral)

  • Manufacturer: UCB INC
    Approval date: May 12, 2016
    Strength(s): 10MG, 25MG, 50MG, 75MG, 100MG [RLD]

Has a generic version of Briviact been approved?

No. There is currently no therapeutically equivalent version of Briviact available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Briviact. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
    Patent 6,784,197
    Issued: August 31, 2004
    Inventor(s): Edmond; Differding & Benoît; Kenda & Bénédicte; Lallemand & Alain; Matagne & Philippe; Michel & Patrick; Pasau & Patrice; Talaga
    Assignee(s): UCB S.A.
    The invention concerns 2-oxo-1-pyrrolidine derivatives of formula (I) wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the invention are particularly suited for treating neurological disorders such as epilepsy.
    Patent expiration dates:
    • February 21, 2021
      ✓ 
      Patent use: TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
    Patent 6,911,461
    Issued: June 28, 2005
    Inventor(s): Differding; Edmond & Kenda; Benoît & Lallemand; Bénédicte & Matagne; Alain & Michel; Philippe & Pasau; Patrick & Talaga; Patrice
    Assignee(s): UCB, S.A.
    The invention concerns 2-oxo-1-pyrrolidine derivatives of formula I, wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the invention are particularly suited for treating neurological disorders such as epilepsy.
    Patent expiration dates:
    • February 21, 2021
      ✓ 
      Patent use: TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
    Patent 8,492,416
    Issued: July 23, 2013
    Assignee(s): UCB Pharma, S.A.
    The invention concerns 2-oxo-1-pyrrolidine derivatives of formula I, wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the invention are particularly suited for treating neurological disorders such as epilepsy.
    Patent expiration dates:
    • February 21, 2021
      ✓ 
      Patent use: TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • May 12, 2021 - NEW CHEMICAL ENTITY

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide